Actuate Therapeutics presented new survival and biomarker data from its Phase 2 clinical program for metastatic pancreatic cancer at ASCO GI. The study showed that the combination of elraglusib and GnP improved survival compared to GnP alone. The trial enrolled 286 patients across 60 clinical sites in six countries and met its primary efficacy endpoints, with a median overall survival of 10.1 months in the elraglusib/GnP arm. The 12-month survival rate was 44.4% for patients receiving elraglusib, compared to 22.3% for chemotherapy alone. Actuate plans to further advance the program to address the unmet need in metastatic pancreatic cancer.

Read more at NASDAQ.: Actuate Says Elraglusib Combo Boosts Survival In Metastatic Pancreatic Cancer